JMP Securities Sticks to Their Buy Rating for Rallybio (RLYB)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYBResearch Report) today and set a price target of $36.00. The company’s shares opened today at $13.53.

Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -7.9% and a 36.03% success rate on recommended stocks.

Rallybio has an analyst consensus of Moderate Buy, with a price target consensus of $36.00.

See today’s best-performing stocks on TipRanks >>

Based on Rallybio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.58 million. In comparison, last year the company had a GAAP net loss of $11.13 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More